Skip to main content

Barrett Esophagus

0
Pipeline Programs
16
Companies
14
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

12 companies ranked by most advanced pipeline stage

PAVmed
PAVmedNY - New York
4 programs
EsoCheckN/A1 trial
EsoGuardN/A1 trial
EsoGuardN/A1 trial
EsoGuardN/A1 trial
Active Trials
NCT05965999Unknown500Est. Jun 2024
NCT06030180Completed566Est. Dec 2024
NCT04293458Completed145Est. Aug 2022
+1 more trials
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
3 programs
EnteroTrackerN/A1 trial
Seattle protocolN/A1 trial
WATS-3D tissue sampling prior to forceps biopsiesN/A
Active Trials
NCT05706025Enrolling By Invitation60Est. Mar 2029
NCT05530343Recruiting2,298Est. Mar 2026
CSA Medical
CSA MedicalMA - Lexington
1 program
CSA SystemN/A1 trial
Active Trials
NCT00321958Terminated23Est. May 2007
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
Cytology Specimen Collection ProcedureN/A1 trial
Active Trials
NCT02890979Completed11Est. Oct 2017
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
Cytology Specimen Collection ProcedureN/A
Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
1 program
Diagnostic TestN/A1 trial
Active Trials
NCT03008980Completed160Est. Dec 2018
Eppendorf
EppendorfGermany - Hamburg
1 program
Endoscopic mucosal resectionN/A1 trial
Active Trials
NCT03427346Unknown407Est. Oct 2025
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Methylene Blue Chromoendoscopy in Barrett's EsophagusN/A1 trial
Active Trials
NCT00587652Completed100Est. Dec 2009
Spine BioPharma
Spine BioPharmaNY - New York
1 program
Pill camN/A
Medtronic
MedtronicNJ - Phillipsburg
1 program
Pill camN/A1 trial
Active Trials
NCT03167970Completed21Est. Jan 2018
Integra LifeSciences
Integra LifeSciencesAustralia - Clayton
1 program
Subjects undergoing TECR with ECM placementN/A1 trial
Active Trials
NCT02396745Terminated1Est. Mar 2018
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
WATS-3D tissue sampling prior to forceps biopsiesN/A1 trial
Active Trials
NCT05056051Unknown200Est. Jun 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Colorado TherapeuticsEnteroTracker
PAVmedEsoCheck
PAVmedEsoGuard
Colorado TherapeuticsSeattle protocol
Angeles TherapeuticsWATS-3D tissue sampling prior to forceps biopsies
PAVmedEsoGuard
PAVmedEsoGuard
MedtronicPill cam
EppendorfEndoscopic mucosal resection
Knight TherapeuticsCytology Specimen Collection Procedure
Integra LifeSciencesSubjects undergoing TECR with ECM placement
Temple TherapeuticsDiagnostic Test
CSA MedicalCSA System
AstraZenecaMethylene Blue Chromoendoscopy in Barrett's Esophagus

Clinical Trials (14)

Total enrollment: 4,962 patients across 14 trials

NCT05706025Colorado TherapeuticsEnteroTracker

Study to Evaluate EnteroTracker® as a Sampling Method to Screen for Barrett's Esophagus/Esophageal Cancer

Start: May 2023Est. completion: Mar 202960 patients
N/AEnrolling By Invitation
NCT05965999PAVmedEsoCheck

Lucid Registry Study

Start: Apr 2023Est. completion: Jun 2024500 patients
N/AUnknown
NCT06030180PAVmedEsoGuard

CLUE: CLinical Utility Study of EsoGuard

Start: Feb 2023Est. completion: Dec 2024566 patients
N/ACompleted
NCT05530343Colorado TherapeuticsSeattle protocol

Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

Start: Oct 2022Est. completion: Mar 20262,298 patients
N/ARecruiting
NCT05056051Angeles TherapeuticsWATS-3D tissue sampling prior to forceps biopsies

Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus

Start: Oct 2020Est. completion: Jun 2025200 patients
N/AUnknown
NCT04295811PAVmedEsoGuard

Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC

Start: Jun 2020Est. completion: Dec 2023470 patients
N/AUnknown
NCT04293458PAVmedEsoGuard

Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE

Start: Feb 2020Est. completion: Aug 2022145 patients
N/ACompleted
NCT03167970MedtronicPill cam

Evaluation of Performance Characteristics of Capsule Endoscopy With PillCam UGI Capsule Compared to Standard Endoscopy

Start: May 2017Est. completion: Jan 201821 patients
N/ACompleted
NCT03427346EppendorfEndoscopic mucosal resection

Neoplastic Barrett Esophagus: Endoscopic Piecemeal vs. En Bloc Resection

Start: Dec 2016Est. completion: Oct 2025407 patients
N/AUnknown
NCT02890979Knight TherapeuticsCytology Specimen Collection Procedure

Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease

Start: Aug 2016Est. completion: Oct 201711 patients
N/ACompleted
NCT02396745Integra LifeSciencesSubjects undergoing TECR with ECM placement

TECR & ECM Placement for Esophageal High Grade Dysplasia

Start: Jan 2016Est. completion: Mar 20181 patients
N/ATerminated
NCT03008980Temple TherapeuticsDiagnostic Test

WATS3D for the Detection of Esophageal Dysplasia

Start: May 2014Est. completion: Dec 2018160 patients
N/ACompleted
NCT00321958CSA MedicalCSA System

Study of Cryotherapy Treatment of Barrett's Esophagus and Early Esophageal Cancer

Start: Apr 2006Est. completion: May 200723 patients
N/ATerminated
NCT00587652AstraZenecaMethylene Blue Chromoendoscopy in Barrett's Esophagus

Methylene Blue Chromoendoscopy in Barrett's Esophagus

Start: Dec 2002Est. completion: Dec 2009100 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 4,962 patients
16 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.